Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets open in the green
Wed, 21 Sep 09:30 am

Most Asian stock markets have opened the day on a firm note. Stock markets in China (up 2.2%), South Korea (up 0.9%) and Malaysia (up 0.7%) are leading the pack of gainers. However, the markets in Indonesia (down 0.5%) and Hong Kong (down 0.2) are trading weak. The Indian stock markets have opened the day on a firm note. Capital goods and banking stocks are leading the gains. However, energy and auto stocks are trading weak.

The BSE-Sensex is trading higher by around 72 points (0.4%), the NSE-Nifty is up by around 22 points (0.4%). The midcap and smallcap stocks are in the positive as well with both the BSE Mid Cap and BSE Small Cap indices up by 0.7% and 0.8% respectively. The rupee is trading at 47.88 to the US dollar.

Cement stocks have opened the day on a mixed note with Ambuja Cements, Birla Corporation, Shree Cement and UltraTech Cement trading in the green. However, Mangalam Cement, Heidelberg Cement and India Cements are facing selling pressure. A report submitted by Serious Fraud Investigation Office (SFIO), the nodal investigation wing of the Ministry of Corporate Affairs, has blamed the leading cement players for abuse of market dominance and cartelization. As per the report, cement players like UltraTech Cement, Ambuja Cements and Associated Cement Companies (ACC) have been colluding to keep the price within a band. The Competition Commission of India is set to commence proceedings against these top cement companies and if found guilty, may impose penalty on them. As per ministry sources, due to such restrictive practices by the companies, about prices being charged were higher by almost 30%, which was in turn hurting the consumers.

Pharma Stocks have opened the day in the green with Lupin and Ranbaxy Lab leading the gains. Mumbai-based pharma major Lupin announced that its US based subsidiary Lupin Pharmaceuticals Inc. (LPI) has been awarded a final approval by US Food and Drug Administration (USFDA) to market a generic version of NOR-QD. NOR-QD is a patented drug of Watson Pharma used for prevention of pregnancy. Lupin will start shipping its norethindrone tablets 0.35 mg within a short time. The total annual sales for NOR-QD and its generic equivalents was approximately US$ 52 m for the trailing 12 months period. The company said that the ANDA (Abbreviated New Drug Application) approval from the U.S. FDA marks Lupin's foray into the U.S. Oral Contraceptive market. Lupin is similarly expecting a couple of other approvals in the year ahead.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open in the green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.